Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


American Heart Association Scientific Sessions, In Brief

Executive Summary

CETP inhibitors gaining traction: Data presented at the American Heart Association's 2009 Scientific Sessions Nov. 14-18 in Orlando, Fla., show that the remaining cholesteryl ester transfer inhibitors - Roche's dalcetrapib and Merck's anacetrapib (MK-0859) - are on track. The CETP class was cast into shadow after Pfizer discontinued work on its potential juggernaut torcetrapib in December 2006 due to elevated blood pressure and increased cardiovascular mortality (1"The Pink Sheet," Dec. 11, 2006). But Roche and Merck have concentrated on learning from the torcetrapib experience and a growing body of evidence shows that dalcetrapib and anacetrapib are sufficiently different from torcetrapib to avoid the negative side effects while still offering the benefit of raising HDL cholesterol (2"The Pink Sheet," Jan. 5, 2009). At AHA, Roche revealed the dal-OUTCOMES study is on track, with 9,000 of the total 15,600 patients enrolled in the morbidity/mortality trial. Roche also announced the initiation of a new, 24-month Phase III clinical trial, dal-PLAQUE 2, to determine the impact of dalcetrapib on artherosclerotic disease progression in more than 900 patients as measured by ultrasound imaging techniques (both intima media thickness and intravenous ultrasound). Additionally, the firm presented preclinical data on dalcetrapib's molecular structure and interaction with CETP to bolster previously reported studies showing the drug's specific mechanism of action. Merck released Phase IIb data showing nearly 600 patients with high cholesterol treated with anacetrapib alone or in combination with atorvastatin showed persistent lipid lowering in the higher-dose arms of the treatment groups. The results strengthen findings originally reported in February 2009 in the American Heart Journal. Data from Merck's Phase III DEFINE trial of anacetrapib are expected in 2010

You may also be interested in...

Set On Competing With Merck And Roche, Dr Reddy's Labs Pins Hopes On CETP Drug

MUMBAI - Despite the odds against developing a robust pipeline of innovative drugs, Kallam Anji Reddy, founder and chairman of the $1.36 billion Dr. Reddy's Labs, refuses to give up the chase to discover new drugs

More Bad News For Genzyme: This Time, A Phase II/III Phosphate Binder Disappoints

Genzyme is scrapping development of a Renvela/Renagel follow-on after it failed to show a significant advantage.

Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive

However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts